Literature DB >> 19211499

Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor.

B I Lévy.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19211499     DOI： 10.1093/annonc/mdp018

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Model-based treatment optimization of a novel VEGFR inhibitor.

Authors:  Ron J Keizer; Anubha Gupta; Robert Shumaker; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 2.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Authors:  Emily S Robinson; Eliyahu V Khankin; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

Review 3.  VEGF inhibition, hypertension, and renal toxicity.

Authors:  Suzanne R Hayman; Nelson Leung; Joseph P Grande; Vesna D Garovic
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

4.  Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.

Authors:  Giovan Giuseppe Di Costanzo; Andrea Casadei Gardini; Giorgia Marisi; Francesco Giuseppe Foschi; Mario Scartozzi; Rocco Granata; Luca Faloppi; Stefano Cascinu; Nicola Silvestris; Oronzo Brunetti; Vincenzo Ostilio Palmieri; Giorgio Ercolani; Raffaella Tortora
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.864

5.  The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

Authors:  Piotr Rutkowski; Elżbieta Bylina; Anna Klimczak; Tomasz Switaj; Sławomir Falkowski; Jacek Kroc; Iwona Lugowska; Magdalena Brzeskwiniewicz; Wojciech Melerowicz; Czesław Osuch; Ewa Mierzejewska; Kacper Wasielewski; Agnieszka Woźniak; Urszula Grzesiakowska; Zbigniew I Nowecki; Janusz A Siedlecki; Janusz Limon
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430

6.  Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

Authors:  Nuria Lainez; Jesús García-Donas; Emilio Esteban; Javier Puente; M Isabel Sáez; Enrique Gallardo; Álvaro Pinto-Marín; Sergio Vázquez-Estévez; Luis León; Icíar García-Carbonero; Cristina Suárez-Rodríguez; Carmen Molins; Miguel A Climent-Duran; Martín Lázaro-Quintela; Aranzazu González Del Alba; María José Méndez-Vidal; Isabel Chirivella; Francisco J Afonso; Marta López-Brea; Nuria Sala-González; Montserrat Domenech; Laura Basterretxea; Carmen Santander-Lobera; Irene Gil-Arnáiz; Ovidio Fernández; Cristina Caballero-Díaz; Begoña Mellado; David Marrupe; José García-Sánchez; Ricardo Sánchez-Escribano; Eva Fernández Parra; José C Villa Guzmán; Esther Martínez-Ortega; María Belén González; Marina Morán; Beatriz Suarez-Paniagua; María J Lecumberri; Daniel Castellano
Journal:  BMC Cancer       Date:  2016-02-22       Impact factor: 4.430

Review 7.  Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.

Authors:  Nuria Mulet-Margalef; Xavier Garcia-Del-Muro
Journal:  Onco Targets Ther       Date:  2016-12-15       Impact factor: 4.147

8.  Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.

Authors:  Jean-David Fumet; François Ghiringhelli; Aurélie Bertaut; Leila Bengrine; Patricia Lapierre; Julie Vincent; Nicolas Falvo
Journal:  Oncotarget       Date:  2017-12-01

Review 9.  New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging.

Authors:  Farah Cadour; Franck Thuny; Joevin Sourdon
Journal:  Front Cardiovasc Med       Date:  2022-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.